Plasmid DNA Manufacturing: Market Size & Forecast 2026

Plasmid DNA manufacturing sits at the upstream pinch point of the gene therapy, cell therapy, and mRNA vaccine value chain, with global biopharma CDMO plasmid-segment revenue in the order of USD 4.2 billion in 2025 (base year) and a forward trajectory running roughly 18-19% CAGR through 2032 as gene therapy approvals compound and mRNA template demand stabilises. The category is structurally tight: GMP-grade bacterial fermentation capacity remains the binding constraint, not the resins or enzymes. A reference SKU (20g GMP-grade purified plasmid lot) prices in the high six to low seven figures, with cost structure anchored by raw materials and skilled labour rather than by petrochemical feedstock pass-through. > **Analyst Take.** Our view: the consensus CAGR sits north of 18% and we would push back modestly. Gene therapy approvals are still ramping but commercial throughput per approved pr

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.